Treatment Use Study of CP-675,206 for Advanced Melanoma
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Tremelimumab (Primary)
- Indications Malignant melanoma
- Focus Expanded access; Therapeutic Use
- Sponsors Pfizer
- 16 Dec 2009 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 10 Dec 2009 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 02 Apr 2008 Status changed from recruiting to in progress, according to clinicaltrials.gov.